Gossamer Bio, Inc. (NASDAQ:GOSS) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $22.50.
Several analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Gossamer Bio in a research report on Monday, October 18th. Zacks Investment Research upgraded Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Monday. SVB Leerink boosted their price target on Gossamer Bio from $15.00 to $16.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 9th. Finally, Piper Sandler started coverage on Gossamer Bio in a research report on Monday, September 20th. They set a “buy” rating and a $26.00 price target for the company.
In related news, insider Laura Carter sold 2,377 shares of the business’s stock in a transaction on Monday, October 25th. The stock was sold at an average price of $12.25, for a total value of $29,118.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 8.00% of the stock is currently owned by insiders.
Shares of Gossamer Bio stock traded down $0.29 on Thursday, reaching $11.25. The company’s stock had a trading volume of 330,112 shares, compared to its average volume of 562,857. The company has a market capitalization of $860.22 million, a P/E ratio of -3.45 and a beta of 0.95. Gossamer Bio has a 52-week low of $7.04 and a 52-week high of $14.30. The stock has a 50-day moving average price of $12.43 and a 200-day moving average price of $9.98. The company has a quick ratio of 10.42, a current ratio of 10.42 and a debt-to-equity ratio of 1.04.
Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Monday, November 8th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.78) by ($0.02). During the same quarter last year, the firm posted ($0.80) earnings per share. Sell-side analysts forecast that Gossamer Bio will post -3.17 earnings per share for the current fiscal year.
Gossamer Bio Company Profile
Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.
Featured Article: What is the Russell 2000 Index?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.